NOAH SALMON: Open Payments
NPI 1558035402 · MESA, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$418 in 27 payments from 7 companies in 2025. Trend: 2023 $388 · 2024 $773 · 2025 $418
Food & beverage: $418
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $195 |
| Alkermes, Inc. | 2 | $53 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| E.R. Squibb & Sons, L.L.C. | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $23 |
Products named: VRAYLAR, REXULTI, CAPLYTA, COBENFY, ARISTADA, FANAPT, VIVITROL.
Industry payments across AZ — which companies pay providers there.
